BACKGROUND: Skeletal myoblast transplantation has been proposed as a therapy for ischemic cardiomyopathy owing to its possible role in myogenesis. The relative safety and efficacy based on location within scar is not known. We hypothesized that skeletal myoblasts transplanted into peripheral scar (compared with central scar) would more effectively attenuate negative left ventricular (LV) remodeling but at the risk of arrhythmia. METHODS: New Zealand White rabbits (n = 34) underwent mid-left anterior descending artery (LAD) ligation to produce a transmural LV infarction. One month after LAD ligation, skeletal myoblasts were injected either in the scar center (n = 13) or scar periphery (n = 10) and compared with saline injection (n = 11). Holter monitoring and magnetic resonance imaging (MRI) was performed pre-injection; Holter monitoring was continued until 2 weeks after injection, with follow-up MRI at 1 month. RESULTS: The centrally treated animals demonstrated increased LV end-systolic volume, end-diastolic volume, and mass that correlated with the number of injected cells. There was a trend toward attenuation of negative LV remodeling in peripherally treated animals compared with vehicle. Significant late ectopy was seen in several centrally injected animals, with no late ectopy seen in peripherally injected animals. CONCLUSIONS: We noted untoward effects with respect to negative LV remodeling after central injection, suggesting that transplanted cell location with respect to scar may be a key factor in the safety and efficacy of skeletal myoblast cardiac transplantation. Administration of skeletal myoblasts into peripheral scar appears safe, with a trend toward improved function in comparison with sham injection.
BACKGROUND: Skeletal myoblast transplantation has been proposed as a therapy for ischemic cardiomyopathy owing to its possible role in myogenesis. The relative safety and efficacy based on location within scar is not known. We hypothesized that skeletal myoblasts transplanted into peripheral scar (compared with central scar) would more effectively attenuate negative left ventricular (LV) remodeling but at the risk of arrhythmia. METHODS: New Zealand White rabbits (n = 34) underwent mid-left anterior descending artery (LAD) ligation to produce a transmural LV infarction. One month after LAD ligation, skeletal myoblasts were injected either in the scar center (n = 13) or scar periphery (n = 10) and compared with saline injection (n = 11). Holter monitoring and magnetic resonance imaging (MRI) was performed pre-injection; Holter monitoring was continued until 2 weeks after injection, with follow-up MRI at 1 month. RESULTS: The centrally treated animals demonstrated increased LV end-systolic volume, end-diastolic volume, and mass that correlated with the number of injected cells. There was a trend toward attenuation of negative LV remodeling in peripherally treated animals compared with vehicle. Significant late ectopy was seen in several centrally injected animals, with no late ectopy seen in peripherally injected animals. CONCLUSIONS: We noted untoward effects with respect to negative LV remodeling after central injection, suggesting that transplanted cell location with respect to scar may be a key factor in the safety and efficacy of skeletal myoblast cardiac transplantation. Administration of skeletal myoblasts into peripheral scar appears safe, with a trend toward improved function in comparison with sham injection.
Authors: Ewout J van den Bos; Richard B Thompson; Anja Wagner; Heiko Mahrholdt; Yoshihisa Morimoto; Louise E J Thomson; Lynn H Wang; Dirk J Duncker; Robert M Judd; Doris A Taylor Journal: Eur J Heart Fail Date: 2005-06 Impact factor: 15.534
Authors: Nabil Dib; Patrick McCarthy; Ann Campbell; Michael Yeager; Francis D Pagani; Susan Wright; W Robb MacLellan; Gregg Fonarow; Howard J Eisen; Robert E Michler; Philip Binkley; Diane Buchele; Ronald Korn; Marwan Ghazoul; Jonathan Dinsmore; Shaun R Opie; Edward Diethrich Journal: Cell Transplant Date: 2005 Impact factor: 4.064
Authors: Tomasz Siminiak; Ryszard Kalawski; Dorota Fiszer; Olga Jerzykowska; Janusz Rzeźniczak; Natalia Rozwadowska; Maciej Kurpisz Journal: Am Heart J Date: 2004-09 Impact factor: 4.749
Authors: D A Taylor; B Z Atkins; P Hungspreugs; T R Jones; M C Reedy; K A Hutcheson; D D Glower; W E Kraus Journal: Nat Med Date: 1998-08 Impact factor: 53.440
Authors: Hanno Huwer; Johannes Winning; Brigitte Vollmar; Cornelius Welter; Christoph Löhbach; Michael D Menger; Hans-Joachim Schäfers Journal: Cell Transplant Date: 2003 Impact factor: 4.064
Authors: Bari Murtuza; Ken Suzuki; George Bou-Gharios; Jonathan R Beauchamp; Ryszard T Smolenski; Terence A Partridge; Magdi H Yacoub Journal: Proc Natl Acad Sci U S A Date: 2004-03-12 Impact factor: 11.205
Authors: Norman Hu; Catherine M Straub; Aida A Garzarelli; Kyle H Sabey; James W Yockman; David A Bull Journal: J Am Assoc Lab Anim Sci Date: 2010-11 Impact factor: 1.232
Authors: Mei Ou; Tae-il Kim; James W Yockman; Bradley A Borden; David A Bull; Sung Wan Kim Journal: J Control Release Date: 2009-10-07 Impact factor: 9.776
Authors: Sarah Fernandes; Harold V M van Rijen; Virginie Forest; Stéphane Evain; Anne-Laure Leblond; Jean Mérot; Flavien Charpentier; Jacques M T de Bakker; Patricia Lemarchand Journal: J Cell Mol Med Date: 2009-03-06 Impact factor: 5.310